Effect of EG00229 on Radiation Resistance of Lung Adenocarcinoma Cells

Lele Cong1, Junxuan Yi2, Shuang Qiu3

  • 1Department of Dermatology, China-Japan Union Hospital, Jilin University, Changchun 130033, Jilin, China.

Journal of Cancer
|September 20, 2021
PubMed

Insights

Neuropilin 1 (NRP1) promotes non-small cell lung cancer (NSCLC) radiation resistance and metastasis. Inhibiting NRP1 with EG00229 reversed resistance by blocking NRP1 and VEGF-165 binding, offering a potential lung cancer radiotherapy strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Neuropilin 1 (NRP1) is a receptor implicated in tumor metastasis and radiation resistance.
  • Its role in non-small cell lung cancer (NSCLC) radiation resistance requires further mechanistic investigation.

Purpose of the Study:

  • To elucidate the mechanistic role of NRP1 in NSCLC radiation resistance.
  • To evaluate the efficacy of EG00229, an NRP1 inhibitor, in reversing radiation resistance in NSCLC cells.

Main Methods:

  • Established radiation-resistant NSCLC cell models (A549RR, H1299-RR).
  • Utilized Western blot, ELISA, qRT-PCR, immunofluorescence, and immunoprecipitation assays.
  • Assessed NRP1, VEGF-165, epithelial-mesenchymal transition (EMT) markers, and related signaling pathways.

Main Results:

  • Radiation-resistant NSCLC cells exhibited increased expression of NRP1, EMT markers, and metastasis-related proteins.
  • EG00229 treatment significantly reduced NRP1 and VEGF-165 expression and binding.
  • EG00229 also decreased the expression of EMT markers and metastasis-related proteins.

Conclusions:

  • NRP1 contributes to NSCLC radiation resistance and metastasis.
  • EG00229 shows potential in reversing NSCLC radiation resistance by inhibiting NRP1-VEGF-165 interaction.
  • Findings support EG00229 as a novel therapeutic strategy for enhancing lung cancer radiotherapy efficacy.

Related Concept Videos